Abstract
Background: Efavirenz as the first-line ARV most frequently used worldwide has a neuropsychiatric side effect that is still debated. Early identification of depressive symptoms determines adherence to treatment. Objective: To determine the prevalence of depressive disorders in a population of HIV patients using efavirenz-based ARVs. Methods: This study used a cross-sectional observational research design with a consecutive sampling method that was conducted at the Sanglah Hospital's Integrated Tropical Disease and Infectious Disease Clinic during May to June 2019. Measurement of depression used the Beck Depression Inventory-II questionnaire. Data analysis used SPSS version 21 with chi square test. Result: The sample size was 90 people, the majority were men (58.9%) with a mean age of 36 ± 7.23 years and a long period of suffering from HIV 5 ± 3.82 years. The population of respondents who received efavirenz-based ARVs was 65.6% with a depression prevalence of 37.3%. The results of the chi-square test analysis showed that there was no significant relationship between the use of Efavirenz-based ARVs and the prevalence of depressive disorders (p = 0.86). Conclusion: More than a third of the sample population had a depressive disorder and was not associated with the use of EFV-based ARVs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
